top of page

ALX Oncology's CEO on CD47 after Gilead's magrolimab news last week, and why he believes his asset is fundamentally different

Feb 14, 2024
1 min read

Jason Lettmann describes how he believes having an inactive Fc domain makes all the difference in the CD47 space, and he previews the clinical data we will see over the course of 2024 to help further this hypothesis.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page